A Chinese vaccine delivers positive results, according to the world’s most respected medical journal. The volunteers who participated in the experiment tolerated it and then raised antibodies.
Increase your business, Not your inbox
Stay up to date and subscribe to our daily newsletter now!
Read for 2 min
This story originally appeared on high level
This May 22nd, the Beijing Biotechnology Institute and the company Tired Biologics, work together to develop a vaccine against COVID-19 announced the results of Phase I of the first vaccine to be launched in the Asian country.
According to an article published in the prestigious medical journal The lancet, The 108 volunteers who participated in the experiment tolerated and made the vaccine safe. In addition, patients were able to produce T-type antibodies.
Adverse symptoms that participants showed were injection site pain, fever, fatigue, headache, and muscle pain. In all cases, however, the severity was mild or moderate.
Different types of antibodies increased significantly along with the specific response of the T cell, which means that Defense mechanisms against the presence of the virus have been created.
According to the report, the antibodies “increased significantly on day 14 and peaked 28 days after vaccination,” so the results warrant further testing.
It should be noted that these results do not mean that the vaccine will be available. Although studies with 500 patients have been included since the start of Phase II in April to further specify the dose appropriate to protect against infection with SARS-CoV-2, the virus that causes COVID-19.
Worldwide, more than 100 projects are funded to develop a vaccine against SARS-CoV-2 and its medical consequences.. Another project, which is part of the United States, plans to start phase III of a vaccine soon, which, if it works, could be available in the fall.
You may be interested: The EU provides 300 million doses of experimental vaccine for COVID-19